论文部分内容阅读
目的:探讨聚乙二醇化重组人粒细胞刺激因子在骨肉瘤新辅助化疗后预防白细胞减少的有效性。方法:A组使用重组人粒细胞集落刺激因子,B组使用PEG-rh G-CSF治疗,对比给药间期的差异。结果:B组白细胞恢复正常天数明显小于A组,差异具有统计学意义(P<0.05)。结论:聚乙二醇化重组人粒细胞刺激因子在骨肉瘤新辅助化疗后,使白细胞恢复正常的时间较重组人粒细胞集落刺激因子短。
Objective: To investigate the effectiveness of pegylated recombinant human granulocyte-stimulating factor in the prevention of neutropenia after neoadjuvant chemotherapy for osteosarcoma. Methods: A group of patients using recombinant human granulocyte colony stimulating factor, B group using PEG-rh G-CSF treatment, compared to the difference between the dosing period. Results: The number of normal white blood cells returned to normal in group B was significantly lower than that in group A (P <0.05). Conclusion: PEGylated recombinant human granulocyte-stimulating factor in neoadjuvant chemotherapy of osteosarcoma, so white blood cells to normal than recombinant human granulocyte colony stimulating factor short.